VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 18, 2013) - BioteQ Environmental Technologies Inc. (TSX:BQE), a leader in the treatment of industrial wastewater, reports its financial and operating results for the fourth quarter and year ended December 31, 2012. All figures are in Canadian dollars.

BioteQ's management will host a conference call to discuss its annual financial results on Tuesday, March 19, 2013 at 10:00 AM eastern time. Participants can dial in at 416-695-7806 or 888-789-9572; participant pass code: 3207139.


2012 was a successful year for BioteQ. In 2012 BioteQ generated the highest level of revenues it has achieved in its history. The company also made significant progress with respect to cash usage levels and further reported progress in a range of operational areas.

At the beginning of 2012, the Company established a set of financial and operational milestones for the year. The following is a summary of our progress against these milestones.

Increase revenues by at least 30%.

Revenues for the year grew 27% over 2011, in line with guidance provided by BioteQ. Total revenues for the year were $9.4 million compared to $7.4 million in 2011. This represents a record level of revenue for the company and was achieved even with the negative impacts associated with significantly lower copper pricing in 2012 vs. 2011.

Further, BioteQ's 2012 revenues do not include the sale of equipment by BioteQ to NWM at NWM's mine site in Mexico. Total proceeds from this sale were USD $650,000. This amount is included in the "Reversal of impairment of Lluvia de Oro operations". Had this sale been to a typical BioteQ customer other than NWM Mining, it would have been accounted for as revenue.

Reduce cash used in operations (including changes in working capital) from $2.5 million in 2011 to less than $1.5 million in 2012 (40% reduction).

Cash usage for the year was also in line with guidance provided by the company in March 2012. Total cash used in operations, after changes in working capital, for 2012 was $1.46 million compared to $2.5 million in 2011 representing a 43% improvement over 2011. BioteQ's adjusted EBITDA improved by 49% from ($3.7) million in 2011 to ($1.9) million in 2012.

Secure an initial sale to a strategic alliance partner

In Q2 2012, BioteQ announced a contract with strategic alliance partner EcoMetales, a wholly-owned subsidiary of Codelco Limited, to conduct laboratory testing and basic engineering relating to arsenic removal for a treatment facility to be built in Chile. The work was completed during the year. The project is now in the next phase of review, which will include environmental and other regulatory approval procedures.

Close sales bookings in Latin America

BioteQ completed engineering review and start-up support services for a Kinross SART project that commenced in 2011. Upon completion of the services, Kinross renewed the ongoing technical support contract into 2013.

In 2012, BioteQ also secured a number of testing contracts with mining companies in South America. One contract was with a leading international mining company to carry out validation test work for the recovery of copper and other high-value trace metals and the removal of arsenic from smelter effluent at a site in Chile, applying the Company's ion exchange technology. The work, which includes laboratory testing and evaluation, was completed in the first quarter of 2013, and will provide the design basis for a commercial plant.

Initial pilot undertaken in a market vertical outside of hard rock mining

BioteQ completed construction of a mobile Sulf-IX™ unit that will provide pilot scale testing for sulphate removal. The mobile pilot plant, a joint initiative with Newalta Corporation, provides on-site field testing for sulphate removal from wastewater. Subsequent to year end, the parties announced the successful commissioning of the unit at a Newalta site. BioteQ also announced it had secured the first test contract for the unit with a US based industrial (non-hard rock mining) customer.


With the exception of Adjusted EBITDA figures, all figures are in accordance with International Reporting Standards (IFRS). Adjusted EBITDA is a non-GAAP measure that is utilized by the Company to provide appropriate transparency of financial results to interested observers. Please refer to the Company's 2012 year end Management's Discussion and Analysis for further details.

Key 2012 financial results were:

  • Total revenues for the year were $9.4 million compared to $7.4 million in 2011 which represents 27% growth over 2011. The increase in revenue over the prior year was mainly due to higher revenue from engineering services and plant sales.
  • Gross margin for the year was $3.7 million, compared to $2.8 million in 2011.
  • Adjusted EBITDA in 2012 was ($1.9) million compared to ($3.7) million in 2011 - a 49% improvement over 2011.
  • Net loss for the year was $3.4 million, or $0.05 per share, compared to a loss of $5.1 million in 2011, or $0.07 per share - a 34% improvement.
  • Cash used in operating activities, after changes in working capital, was $1.5 million compared to $2.5 million in 2011 - a 43% improvement year over year.
  • Working capital at the end of 2012 was $7.4 million which included $7.5 million in cash and short-term investments.


BioteQ had three active water treatment operations contributing to revenue during the fourth quarter - plants in Arizona, Quebec, and China. BioteQ had concluded its water treatment operations at a fourth site in the Yukon in mid July. Combined, the plants treated 2.2 million cubic metres of water during the quarter, and removed over 288,000 pounds of metals from the environment, bringing total production for the 2012 year to over 10.6 million cubic metres of water treated and 2.5 million pounds of metal recovered.

The Bisbee, Arizona operation produced approximately 123,000 pounds of copper and treated 253,000 cubic metres of water during the quarter, bringing total production to 492,000 pounds of copper and 974,000 cubic metres of water treated for the year. Revenues for this operation are based on the sale of copper recovered.

The Dexing, China operation produced approximately 165,000 pounds of copper and treated 1.7 million cubic metres of water during the fourth quarter, bringing total production to 2 million pounds of copper and 8.7 million cubic metres of water treated for the year. The operation was inactive for a portion of Q4 due to routine annual plant maintenance. Revenues from this operation are based on the sale of copper recovered.

The Raglan, Quebec ChemSulphide® plant concluded its operating season in late November and treated 241,000 cubic metres of water during the fourth quarter. Year-to-date treatment volumes were 864,000 cubic metres, slightly lower than originally forecast, due to lower than expected precipitation levels over the treatment season. Revenues for this seasonal operation are based on fees for the volume of water treated.


During the year, BioteQ continued to build its business of providing technology solutions - including design, engineering, commissioning and other technical services to mining and other industrial customers.

  • In Q1 2012, BioteQ delivered a mobile ion exchange water treatment plant to an international mining customer.
  • BioteQ and its joint venture partner Jiangxi Copper Company announced plans to build a second ChemSulphide® copper recovery plant at the Dexing site. The plant is expected to be completed by Q3 2013 at a total cost of approximately $3 million.
  • BioteQ obtained 7 paid testing contracts relating to a number of different applications. These testing contracts typically constitute the initial phase in the development of projects that could lead to the provision of full-scale treatment plants.
  • Significant technology development progress was made in the areas of:
    • Selective high-value metals recovery (one test contract signed); and
    • Selenium removal (two test contracts signed).


2012 was the first year in which BioteQ began to implement its new corporate strategy. It was also a year in which the Company strived to show measured but meaningful financial and operational progress. However, the primary focus for the Company in 2012 was to lay the foundation that would enable continuing rapid growth over the coming 5 years.

In 2012 BioteQ achieved a record level of revenue and reduced its cash used in operations by over 40%. In addition, the Company made several operational changes that included:

  • Creation of a focused and dedicated sales and marketing organization;
  • Establishment of a technology innovation and business development function; and
  • Enhanced and made more rigorous our engineering and project execution functions.

In 2013, BioteQ expects to continue to build on the progress made in 2012. Key financial milestones for 2013 are:

  1. Revenue

The Company expects to grow revenue in 2013, on a proportionate revenue basis, by 25% over 2012 to approximately $11.8 million. Revenue growth is expected to be generated from: the completion of plants currently under construction at the Dexing site; large scale piloting campaigns with customers in North and South America; plant sales; and engineering and technical development projects.

  1. Adjusted EBITDA

BioteQ will provide guidance for 2013 and beyond in terms of Adjusted EBITDA (adjusted to exclude the effects of foreign exchange and stock based compensation charges). BioteQ believes that this non-GAAP measure will provide investors and observers with enhanced transparency and understanding of the underlying performance of the Company.

In 2012, BioteQ's adjusted EBITDA was ($1.9) million. For 2013, the Company expects to improve its adjusted EBITDA by approximately 50% to less than ($1 million). The projected improvement in adjusted EBITDA is expected to come from additional margin generated via increased sales revenues and from continued improvements in the efficiency of our operating and engineering activities.

Jonathan Wilkinson, BioteQ's Chief Executive Officer, stated "2012 was a year in which significant progress was made with regard to development and implementation of a new strategy that we believe will stabilize the existing business and provide a platform for rapid growth going forward. Given the numerous financial, sales and operational accomplishments made by the company over the past 12 months, I believe that we are poised for sustained growth and that we are well on our way towards creating a robust, innovative and financially sound organization."

BioteQ Corporate Profile

BioteQ is an innovative clean technology leader in global industrial water treatment, serving the mining and energy markets. The company's proven technologies have been applied at sites around the world to recover dissolved metals and remove sulphate, producing clean water and eliminating residual waste. BioteQ is headquartered in Vancouver, Canada and trades on the TSX under the symbol BQE. Please visit our website at for additional information.


Certain information contained herein may not be based on historical fact and therefore constitutes "forward-looking information" under applicable Canadian securities legislation. This includes without limitation statements containing the words "plan", "expect", "project", "estimate", "intend", "believe", "anticipate", "may", "will" and other similar words or expressions. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's dependence on key personnel and contracts, uncertainty with respect to the profitability of the Company's technologies, competition, technology risk, the Company's ability to protect its intellectual property and proprietary information, fluctuations in commodity prices, currency risk, environmental regulation and the Company's ability to manage growth and other factors described in the Company's filings with the Canadian securities regulators at (including without limitation the factors described in the section entitled "Risks and Uncertainties" in the Company's Annual Report for the year ended December 31, 2012 and the section entitled "Risk Factors" in the Company's Annual Information Form for the year ended December 31, 2012). Given these risks and uncertainties, the reader is cautioned not to place undue reliance on forward-looking statements. All forward-looking information contained herein is based on management's current expectations and the Company undertakes no obligation to revise or update such forward-looking information to reflect subsequent events or circumstances, except as required by law.

BioteQ Environmental Technologies Inc.
Consolidated Statement of Financial Position
As at December 31, 2012 and 2011
Dec 31 2012 Dec 31 2011
$ $
Current assets
Cash and cash equivalents 5,594,154 4,774,970
Short-term investments 1,934,572 4,486,097
Trade receivables 1,380,672 1,664,326
Receivable from joint venture partners (note 17) 159,724 182,286
Net insurance proceeds receivable (note 20) - 637,099
Taxes recoverable 41,131 153,889
Inventory (note 7) 89,957 48,174
Work in progress 229,797 432,261
Other receivable and prepaid expenses 306,641 222,709
9,736,648 12,601,811
Non-current assets
Property, plant and equipment (note 4, 8 and 16) 5,582,740 6,615,837
Intangible asset 38,710 69,682
Total assets 15,358,098 19,287,330
Current liabilities
Accounts payable and accrued liabilities 1,976,636 2,659,249
Deferred revenue 91,970 340,185
Taxes payable 251,930 63,105
Deferred lease inducement 60,090 18,945
2,380,626 3,081,484
Non-current liabilities
Deferred income tax liability (note 13) 146,140 88,713
Long-term liabilities (note 9) 84,723 111,146
Total liabilities 2,611,489 3,281,343
Shareholders' Equity
Capital stock and warrants (note 10) 55,269,416 55,269,416
Contributed surplus 8,247,007 8,117,400
Accumulated other comprehensive loss (1,097,611) (1,075,369)
Deficit (49,672,203) (46,305,460)
Total shareholders' equity 12,746,609 16,005,987
Total liabilities and shareholders' equity 15,358,098 19,287,330
Contingency (note 20)
Commitments(note 21)
Subsequent event(note 23)
Approved by the Board of Directors
"Jonathan Wilkinson" "G. W. Poling"
Jonathan Wilkinson, Director G.W. Poling, Director
The accompanying notes are an integral part of these consolidated financial statements.
BioteQ Environmental Technologies Inc.
Consolidated Statements of Operations and Comprehensive Loss
For the years ended December 31, 2012 and 2011
2012 2011
$ $
Revenue 9,424,179 7,413,797
Plant and other operating costs (not including depreciation) 5,769,513 4,654,065
3,654,666 2,759,732
General and administration 4,822,446 4,991,527
Sales and development 1,555,154 955,225
Stock-based compensation (note 10) 129,607 101,878
Depreciation of property, plant and equipment (note 8) 945,098 664,038
Amortization of intangible asset 30,972 30,972
Loss before the under-noted (3,828,611) (3,983,908)
Interest income 48,602 122,418
Other income 11,886 2,376
Foreign exchange gain (loss) 33,915 (204,519)
Write-down of capital assets (note 8) - (554,565)
Reversal of impairment of Lluvia de Oro operations (note 6) 1,226,873 -
Impairment of reagent (note 4) (394,214) -
Loss before income taxes (2,901,549) (4,618,198)
Income taxes (note 13) 465,194 472,257
Net loss for the year (3,366,743) (5,090,455)
Other comprehensive income (loss)
Cumulative translation adjustment (22,242) 407,576
Comprehensive loss for the year (3,388,985) (4,682,879)
Net loss per share
Basic and diluted (0.05) (0.07)
Weighted average number of shares outstanding
Basic and diluted 69,966,672 69,949,120
The accompanying notes are an integral part of these consolidated financial statements.
BioteQ Environmental Technologies Inc.
Consolidated Statement of Changes in Equity
For the years ended December 31, 2012 and 2011
Number of shares
Capital stock

Contributed surplus Accumulated
income (loss)


$ $ $ $ $ $
Balance - January 1, 2011 69,865,006 53,668,812 1,513,417 8,045,826 (1,482,945) (41,215,005) 20,530,105
Stock-based compensation (note 10) - - - 101,878 - - 101,878
Exercise of options 101,666 87,187 - (30,304) - - 56,883
Net loss for the year - - - - - (5,090,455) (5,090,455)
Other comprehensive loss for the year - - - - 407,576 - 407,576
Balance - December 31, 2011 69,966,672 53,755,999 1,513,417 8,117,400 (1,075,369) (46,305,460) 16,005,987
Balance - January 1, 2012 69,966,672 53,755,999 1,513,417 8,117,400 (1,075,369) (46,305,460) 16,005,987
Stock-based compensation (note 10) - - - 129,607 - - 129,607
Net loss for the year - - - - - (3,366,743) (3,366,743)
Other comprehensive income for the year - - - - (22,242) - (22,242)
Balance - December 31, 2012 69,966,672 53,755,999 1,513,417 8,247,007 (1,097,611) (49,672,203) 12,746,609
The accompanying notes are an integral part of these consolidated financial statements.
BioteQ Environmental Technologies Inc.
Consolidated Statement of Cash Flow
For the years ended December 31, 2012 and 2011
2012 2011
$ $
Cash flow used in
Operating activities
Net loss for the period (3,366,743) (5,090,455)
Items not affecting cash:
Depreciation of property, plant and equipment 945,098 664,038
Amortization of intangible asset 30,972 30,972
Amortization of deferred lease inducement (22,328) (28,417)
Deferred income tax 57,427 88,713
Write down of capital asset (note 8) - 554,565
Impairment of reagent (note 4) 394,214 -
Loss on disposal of equipment - 6,171
Unrealized foreign exchange loss 29,548 230,021
Interest income (14,880) (99,110)
Stock-based compensation charge (note 10) 129,607 101,878
(1,817,085) (3,541,624)
Change in non-cash working capital items (note 15) 354,309 992,968
Net cash used in operating activities (1,462,776) (2,548,656)
Investing activities
Purchase of property, plant and equipment (559,678) (984,892)
Proceeds on disposal of equipment - 12,604
Receipt of government grant (note 19) 277,550 -
Purchase of short-term investments (3,908,203) (14,053,596)
Proceeds from sale of short-term investments 6,474,608 17,624,000
Net cash provided by investing activities 2,284,277 2,598,116
Financing activities
Proceeds from exercise of options - 56,883
Increase in deferred lease inducement 63,473 -
Increase (decrease) in long-term liabilities (26,423) 64,262
Net cash provided by financing activities 37,050 121,145
858,551 170,605
Effect of exchange rate changes on cash (39,367) (49,100)
Increase in cash 819,184 121,505
Beginning of period 4,774,970 4,653,465
End of period 5,594,154 4,774,970
The accompanying notes are an integral part of these consolidated financial statements.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release.

Contact Information:

BioteQ Environmental Technologies Inc.
Suite 1000 - 1050 West Pender St
Vancouver BC V6E 3S7

BioteQ Environmental Technologies Inc.
Jonathan Wilkinson
604.685.1243 or 1.800.537.3073

BioteQ Environmental Technologies Inc.
Paul Kim
604.685.1243 or 1.800.537.3073